Melissa Dodds

Melissa Dodds

Auto-generated profile, based on publicly available information

Melissa Dodds

From the Department of Dermatology (S.M., M.D.), Biostatistics Core, Masonic Cancer Center (N.R.), and Department of Pediatrics (C.M.), University of Minnesota, Minneapolis; Department of Clinical Genetics (Y.B., C.W.), Royal North Shore Hospital; Faculty of Medicine (Y.B.), University of Sydney, Australia; and Department of Neurology and Cancer Center (S.R.P.), Massachusetts General Hospital, Boston

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2020 in Pediatric Dermatology
Verified
Journal Article
Closed access
PDF file
MDMelissa Dodds
Melissa Dodds
MTMegha Tollefson
Megha Tollefson
LCLeslie Castelo‐Soccio
Leslie Castelo‐Soccio
MGMaria C. Garzon
Maria C. Garzon
MHMarcia Hogeling
Marcia Hogeling
SMSheilagh Maguiness
Sheilagh Maguiness

17 August 2021 in Neurology
Verified
Journal Article
Closed access
PDF file
SMSheilagh Maguiness
Sheilagh Maguiness
YBYemima Berman
Yemima Berman
NRNathan Rubin
Nathan Rubin
MDMelissa Dodds
Melissa Dodds
Scott PlotkinScott Plotkin
Scott Plotkin
OCon behalf of the REiNS International Collaboration
on behalf of the REiNS International Collaboration
Objective In order to explore the use of Skindex scoring in patients with neurofibromatosis type 1 (NF1) across multiple clinical sites and inform design of additional quality of life measures, we analyzed correlations between Skindex, site, and clinical measures for 79 patients with NF1 from specialized clinics in Sydney, Australia (Royal North Shore Hospital [RNS]) and Minneapolis, Minnesota (University of Minnesota [UMN]). Methods The relationship between clinical factors and Skindex scores were explored by clinic site and overall. Results A total of 40 participants were recruited from RNS and 39 from UMN. Female sex, total number of cutaneous neurofibroma (cNF), and whether cNF were present on the face correlated highly with Skindex and not Riccardi scores. The UMN site had lower average scores, but these differences were almost entirely removed after adjusting for age, sex, facial cNF, and total cNF number. Conclusions The development of cNF in adolescence and adulthood in NF1 often leads to progressive disfigurement and discomfort and is among one of the most common reasons for patients to seek medical treatment. Skindex has been used to assess skin-related quality of life in NF1 previously but is not specific to NF1. These findings highlight the need for a low threshold for referral to dermatologists for all patients with NF1 regardless of the severity of disease. The finding that facial cNF and higher total number of cNF correlates with poorer skin-related quality of life may benefit design of more specific NF1 skin-related quality of life measures.

15 April 2019 in Pediatric Dermatology
Verified
Journal Article
Closed access
PDF file
MDMelissa Dodds
Melissa Dodds
SMSheilagh Maguiness
Sheilagh Maguiness

23 March 2018 in Pediatric Dermatology
Verified
Journal Article
Closed access
PDF file
MDMelissa Dodds
Melissa Dodds
PHPatricia Hobday
Patricia Hobday
BSBrittney Schultz
Brittney Schultz
SMSheilagh Maguiness
Sheilagh Maguiness